Skip to content

Septerna, Inc. SEPN Return on equity

Return on equity at other companies

Amgen logo
AmgenAMGN
101.3%-4.4pp
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-45.6%-66.1pp
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
-28.3%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-61.4%-2.5pp
Fortrea Holdings Inc. logo
Fortrea Holdings Inc.FTRE
-64.5%0.0pp
Precigen logo
PrecigenPGEN
-843.6%-1,103pp

Other financials

Income statement

See full
Revenue$26.5M+12,011%
Operating income-$13.3M+48.7%
Net income-$8.6M+59.8%
EPS (diluted)-$0.19+61.2%

Balance sheet

See full
Cash & equivalents$71.6M-65.9%
Total debt$23.1M-7.7%
Total equity$378.5M+195%
Total assets$569.7M+31.3%

Cash flow

See full
Operating cash flow-$25.6M-9.8%
CapEx$832.0K+118%
Free cash flow-$26.5M-11.5%

Valuation

See full
Market cap$1.65B+319%
Enterprise value$1.6B+1,325%
P/S22.8×-379×

Profitability

See full
Operating margin-77.1%-38.4pp
Net margin-49.9%-24.9pp
FCF margin467.9%+243pp

Returns & leverage

See full
Debt / equity0.1×
Current ratio4.7×-27.5×

Where this comes from

Calculated from Septerna, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Septerna, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Septerna, Inc.'s return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Septerna, Inc.'s return on equity?
Septerna, Inc. (SEPN) reported return on equity of -12.2% in Q4 2025.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.